Cibo Huang

机构：National Health and Family Planning Commission, Second Affiliated Hospital of Guangzhou Medical University, Beijing Municipal Government, Beijing Hospital, State Council of the People's Republic of China, University of Hong Kong - Shenzhen Hospital, Guangzhou Medical University · ORCID：0000-0001-6706-7750

发表论文 92 篇 · 总被引 1966 次 · h-index 25

代表论文

• Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial (2023 · Annals of the Rheumatic Diseases · 被引 146)
• Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial (2023 · Lara D. Veeken · 被引 75)
• 2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis (2021 · Rheumatology and Immunology Research · 被引 47)
• A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus (2025 · New England Journal of Medicine · 被引 36)
• Multidisciplinary Guidelines for the Rational Use of Topical Non-Steroidal Anti-Inflammatory Drugs for Musculoskeletal Pain (2022) (2023 · Journal of Clinical Medicine · 被引 27)
• 2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint (2021 · Aging Clinical and Experimental Research · 被引 26)